142 related articles for article (PubMed ID: 27102439)
1. The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma.
Boregowda RK; Medina DJ; Markert E; Bryan MA; Chen W; Chen S; Rabkin A; Vido MJ; Gunderson SI; Chekmareva M; Foran DJ; Lasfar A; Goydos JS; Cohen-Solal KA
Oncotarget; 2016 May; 7(20):29689-707. PubMed ID: 27102439
[TBL] [Abstract][Full Text] [Related]
2. RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.
Boregowda RK; Olabisi OO; Abushahba W; Jeong BS; Haenssen KK; Chen W; Chekmareva M; Lasfar A; Foran DJ; Goydos JS; Cohen-Solal KA
Cancer Lett; 2014 Jun; 348(1-2):61-70. PubMed ID: 24657655
[TBL] [Abstract][Full Text] [Related]
3. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
4. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.
Dugo M; Nicolini G; Tragni G; Bersani I; Tomassetti A; Colonna V; Del Vecchio M; De Braud F; Canevari S; Anichini A; Sensi M
Oncotarget; 2015 Mar; 6(7):5118-33. PubMed ID: 25742786
[TBL] [Abstract][Full Text] [Related]
5. Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.
Capaldo BJ; Roller D; Axelrod MJ; Koeppel AF; Petricoin EF; Slingluff CL; Weber MJ; Mackey AJ; Gioeli D; Bekiranov S
PLoS One; 2015; 10(9):e0138210. PubMed ID: 26405815
[TBL] [Abstract][Full Text] [Related]
6. Role of Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in MCF-10A cells.
Tandon M; Chen Z; Pratap J
J Cell Biochem; 2014 Dec; 115(12):2208-17. PubMed ID: 25147082
[TBL] [Abstract][Full Text] [Related]
7. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
[TBL] [Abstract][Full Text] [Related]
8. An essential role of discoidin domain receptor 2 (DDR2) in osteoblast differentiation and chondrocyte maturation via modulation of Runx2 activation.
Zhang Y; Su J; Yu J; Bu X; Ren T; Liu X; Yao L
J Bone Miner Res; 2011 Mar; 26(3):604-17. PubMed ID: 20734453
[TBL] [Abstract][Full Text] [Related]
9. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression.
Cohen-Solal KA; Boregowda RK; Lasfar A
Mol Cancer; 2015 Jul; 14():137. PubMed ID: 26204939
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
Lee C
Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
[TBL] [Abstract][Full Text] [Related]
11. RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target.
Thamm DH; Huelsmeyer MK; Mitzey AM; Qurollo B; Rose BJ; Kurzman ID
Melanoma Res; 2010 Feb; 20(1):35-42. PubMed ID: 19949352
[TBL] [Abstract][Full Text] [Related]
12. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone attenuates the transcriptional activity of Runx2 by facilitating its physical association with Stat3beta.
Ziros PG; Georgakopoulos T; Habeos I; Basdra EK; Papavassiliou AG
J Bone Miner Res; 2004 Nov; 19(11):1892-904. PubMed ID: 15476590
[TBL] [Abstract][Full Text] [Related]
14. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
Prahallad A; Heynen GJ; Germano G; Willems SM; Evers B; Vecchione L; Gambino V; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Bernards R
Cell Rep; 2015 Sep; 12(12):1978-85. PubMed ID: 26365186
[TBL] [Abstract][Full Text] [Related]
15. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.
Wu X; Zhou J; Rogers AM; Jänne PA; Benedettini E; Loda M; Hodi FS
Melanoma Res; 2012 Apr; 22(2):123-32. PubMed ID: 22343486
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional upregulation of DDR2 by ATF4 facilitates osteoblastic differentiation through p38 MAPK-mediated Runx2 activation.
Lin KL; Chou CH; Hsieh SC; Hwa SY; Lee MT; Wang FF
J Bone Miner Res; 2010 Nov; 25(11):2489-503. PubMed ID: 20564243
[TBL] [Abstract][Full Text] [Related]
17. A Potential Role of RUNX2- RUNT Domain in Modulating the Expression of Genes Involved in Bone Metastases: An In Vitro Study with Melanoma Cells.
Deiana M; Dalle Carbonare L; Serena M; Cheri S; Mutascio S; Gandini A; Innamorati G; Lorenzi P; Cumerlato M; Bertacco J; Antoniazzi F; Romanelli MG; Mottes M; Zipeto D; Valenti MT
Cells; 2020 Mar; 9(3):. PubMed ID: 32204402
[TBL] [Abstract][Full Text] [Related]
18. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Interplay of RUNX2 and CXCR4 in Melanoma Progression.
Dalle Carbonare L; Minoia A; Vareschi A; Piritore FC; Zouari S; Gandini A; Meneghel M; Elia R; Lorenzi P; Antoniazzi F; Pessoa J; Zipeto D; Romanelli MG; Guardavaccaro D; Valenti MT
Cells; 2024 Feb; 13(5):. PubMed ID: 38474372
[TBL] [Abstract][Full Text] [Related]
20. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth.
Yoshida M; Selvan S; McCue PA; DeAngelis T; Baserga R; Fujii A; Rui H; Mastrangelo MJ; Sato T
Pigment Cell Melanoma Res; 2014 Mar; 27(2):297-308. PubMed ID: 24354797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
